Literature DB >> 17065180

Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.

Alper O Onbasili1, Yavuz Yeniceriglu, Pinar Agaoglu, Aslihan Karul, Tarkan Tekten, Harun Akar, Guzel Discigil.   

Abstract

OBJECTIVE: To evaluate the efficacy of trimetazidine (TMZ) in the prevention of contrast-induced nephropathy (CIN) in patients with high serum creatinine levels undergoing coronary angiography/angioplasty.
METHODS: TMZ (20 mg thrice daily) was administered orally for 72 h starting 48 h before the procedure. All patients were given intravenous saline (0.9%) at a rate of 1 ml/kg of body weight per hour for 24 h starting 12 h beforehand. Serum creatinine levels were measured before the procedure, 48 h and 7 days after the procedure. Increase in serum creatinine level exceeding 0.5 mg/day or one quarter of the basal value is considered as CIN. Venous blood samples for serum total antioxidant capacity (TAC) measurement were drawn before and after coronary angiography.
RESULTS: Basal serum creatinine levels and TAC were similar in TMZ and control groups. Serum creatinine levels in the control group increased significantly 2 days after the procedure, and returned to the baseline values on the seventh day. However, it did not change significantly on the second day, and even significantly decreased on the seventh day in the TMZ group. CIN developed in 2.5% (1/40) of patients in the TMZ group and in 16.6% (7/42) of patients in the control group (p<0.05). TAC values were not different between treatment groups.
CONCLUSION: TMZ along with isotonic saline infusion is more effective than isotonic saline alone in reducing the risk of CIN in patients with pre-existing renal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17065180      PMCID: PMC1955192          DOI: 10.1136/hrt.2006.097477

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  54 in total

Review 1.  Contrast nephropathy.

Authors:  Sean W Murphy; Brendad J Barrett; Patrick S Parfrey
Journal:  J Am Soc Nephrol       Date:  2000-01       Impact factor: 10.121

2.  Acetylcysteine and nephrotoxic effects of radiographic contrast agents--a new use for an old drug.

Authors:  R Safirstein; L Andrade; J M Vieira
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

3.  Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).

Authors:  Larry J Diaz-Sandoval; Bernard D Kosowsky; Douglas W Losordo
Journal:  Am J Cardiol       Date:  2002-02-01       Impact factor: 2.778

4.  Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient.

Authors:  A Zoppo; A Faggiotto; L Redaelli; S Campi; A L Catapano
Journal:  Transplantation       Date:  1999-10-27       Impact factor: 4.939

5.  Effects of non-ionic monomeric and dimeric iodinated contrast media on renal and systemic haemodynamics in rats.

Authors:  J M Idée; E Lancelot; C Berthommier; V Couturier-Goulas; V Vazin; C Corot
Journal:  Fundam Clin Pharmacol       Date:  2000 Jan-Feb       Impact factor: 2.748

6.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.

Authors:  M Tepel; M van der Giet; C Schwarzfeld; U Laufer; D Liermann; W Zidek
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

7.  Does post-angiographic hemodialysis reduce the risk of contrast-medium nephropathy?

Authors:  G Sterner; B Frennby; J Kurkus; U Nyman
Journal:  Scand J Urol Nephrol       Date:  2000-10

8.  The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

Authors:  P F Kantor; A Lucien; R Kozak; G D Lopaschuk
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

9.  The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency.

Authors:  L Gruberg; G S Mintz; R Mehran; G Gangas; A J Lansky; K M Kent; A D Pichard; L F Satler; M B Leon
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

10.  Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.

Authors:  Ioannis Iakovou; George Dangas; Roxana Mehran; Alexandra J Lansky; Dale T Ashby; Martin Fahy; Gary S Mintz; Kenneth M Kent; Augusto D Pichard; Lowell F Satler; Gregg W Stone; Martin B Leon
Journal:  J Invasive Cardiol       Date:  2003-01       Impact factor: 2.022

View more
  19 in total

1.  Preventing contrast nephropathy in catheter laboratory.

Authors:  Jeffrey W H Fung; Check C Szeto; Cheuk M Yu
Journal:  Heart       Date:  2007-06       Impact factor: 5.994

Review 2.  Prevention of Contrast and Radiation Injury During Coronary Angiography and Percutaneous Coronary Intervention.

Authors:  Arash Ehteshami Afshar; Puja B Parikh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-22

3.  The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.

Authors:  Xingji Lian; Wenfei He; Huimin Zhan; Jiyan Chen; Ning Tan; Pengcheng He; Yuanhui Liu
Journal:  Int Urol Nephrol       Date:  2019-10-22       Impact factor: 2.370

4.  Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.

Authors:  M Cavar; M Ljubkovic; C Bulat; D Bakovic; D Fabijanic; J Kraljevic; N Karanovic; Z Dujic; C J Lavie; U Wisloff; J Marinovic
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

Review 5.  Activators of SIRT1 in the kidney and protective effects of SIRT1 during acute kidney injury (AKI) (effect of SIRT1 activators on acute kidney injury).

Authors:  Alireza Raji-Amirhasani; Mohammad Khaksari; Fatemeh Darvishzadeh Mahani; Zahra Hajializadeh
Journal:  Clin Exp Nephrol       Date:  2021-03-29       Impact factor: 2.801

6.  Protective Role of Trimetazidine Against Neomycin-induced Hair Cell Damage in Zebrafish.

Authors:  Jiwon Chang; Gi Jung Im; Sung Won Chae; Seung Hoon Lee; Soon-Young Kwon; Hak Hyun Jung; Ah-Young Chung; Hae-Chul Park; June Choi
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-11-29       Impact factor: 3.372

Review 7.  Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors.

Authors:  Michele Andreucci; Teresa Faga; Antonio Pisani; Massimo Sabbatini; Domenico Russo; Ashour Michael
Journal:  ScientificWorldJournal       Date:  2014-11-30

8.  Effect of trimetazidine on preventing contrast-induced nephropathy in diabetic patients with renal insufficiency.

Authors:  Ziliang Ye; Haili Lu; Qiang Su; Xinhua Xian; Lang Li
Journal:  Oncotarget       Date:  2017-07-24

9.  Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study).

Authors:  Young-Guk Ko; Byoung-Kwon Lee; Woong Chol Kang; Jae-Youn Moon; Yun Hyeong Cho; Seong Hun Choi; Myeong-Ki Hong; Yangsoo Jang; Jong-Youn Kim; Pil-Ki Min; Hyuck-Moon Kwon
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

10.  The effect of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rats.

Authors:  Murat Boyacioglu; Hulya Turgut; Cagdas Akgullu; Ufuk Eryilmaz; Cavit Kum; Osman Alper Onbasili
Journal:  J Vet Med Sci       Date:  2013-08-20       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.